Quality of life in women with chronic recurrent vulvovaginal candidosis: A sub‐analysis of the prospective multicentre phase IIb/III Prof‐001 study

Abstract

AbstractBackgroundChronic recurrent vulvovaginal candidosis (RVVC), defined as three or more episodes of vulvovaginal candidosis per year, significantly impairs quality of life (QoL) and sexual health.ObjectivesThe primary objective of this study was to assess health‐related QoL in women with RVVC using validated questionnaires before and after treatment. The secondary objective was to analyse the effect of RVVC on women's sexual health.Patients/MethodsThis was a sub‐analysis of a randomised, controlled, double‐blinded study titled ‘A phase IIb/III, parallel‐arm, randomized, active‐controlled, double‐blind, double‐dummy, multicenter, non‐inferiority study in patients with recurrent vulvovaginal candidosis to compare the clinical efficacy, safety and tolerability of topically administered ProF‐001 (Candiplus®) to oral fluconazole, which was conducted at 35 study sites in Austria, Poland and Slovakia. QoL was assessed using the European Quality of Life (EQ) five‐dimension five‐level scale (EQ‐5D‐5L) and visual analogue scale (EQ‐VAS) questionnaires, followed by specific questions regarding sexuality.ResultsFrom 2019 to 2021, 360 of 432 (83.3%) women with RVVC had accomplished a 6‐months maintenance treatment and were enrolled in this sub‐analysis. The EQ‐5D‐5L and EQ‐VAS scores demonstrated improved QoL in 137 (65.2%) and 159 (75.4%) women after 6 months of maintenance treatment. Each individual aspect of sexual health significantly improved (all p < .05). A reduction in pain frequency during or after sexual intercourse in the 6‐month period occurred in 124 (66.3%) women.ConclusionsWomen with RVVC had high QoL and sexual health impairment; however, a 6‐months maintenance treatment resulted in effective improvement in QoL and sexual health.